Tracking low platelet counts over time in antiphospholipid syndrome
Follows changes in platelet counts in adults with antiphospholipid syndrome.
Key facts
- Who runs it
- New Valley University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Platelet count
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed diagnosis of antiphospholipid syndrome (APS). It follows their platelet counts over time.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Definite APS by Sydney criteria, with blood clots and/or pregnancy problems.
- Biomarker or test result
- Antiphospholipid antibodies (aPL) must stay positive over time. At least 3 recorded platelet counts over at least 12 months before joining.
Main reasons for not taking part
- Low platelets clearly caused by something other than APS, such as chemotherapy, myelodysplastic syndromes, cirrhosis or HIV
- Other conditions that strongly affect survival on their own, such as cancer that has spread, as judged by the study doctor
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age ≥18 years
- Definite APS by Sydney criteria (thrombotic and/or obstetric) with persistent aPL positivity
- ≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)
Who cannot take part
- Concomitant conditions strongly affecting survival independent of APS (e.g., metastatic cancer), at investigator discretion
- Thrombocytopenia clearly attributable to non APS causes (e.g., chemotherapy, myelodysplastic syndromes, cirrhosis, HIV)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Thrombocytopenia is common in antiphospholipid syndrome (APS) and is now included in the 2023 ACR/EULAR APS criteria as an important non criteria/hematologic feature. Persistent or low-moderate thrombocytopenia independently predicts reduced long-term survival in APS, with hazard ratios for mortality around 2.7-4.4, and is associated with a severe disease phenotype and thrombotic deaths.
The group in the trial
- Antiphospholipid syndrome patientsTreatment being tested
* Definite APS by Sydney criteria (thrombotic and/or obstetric) with persistent aPL positivity. * ≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)
Treatment: Platelet count
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Thrombocytopenia Trajectories as a Dynamic Biomarker of Clinical Severity and Survival in Antiphospholipid Syndrome: A Multicenter Cohort Study
- Plain-language title
- Tracking low platelet counts over time in antiphospholipid syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 28 October 2026